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regulatory regions of multiple genes encoding 
proteins (such as prostate‑specific antigen) 
that are critical for prostate differentiation 
and for its normal functions. Significantly, 
the consistent expression of AR in PCa, and 
its continued activity in PCa that relapse 
after androgen deprivation therapy (CRPC), 
indicate that at least a subset of these genes 
are also critical for PCa development and 
progression. However, the identity of the 
AR regulated genes that are critical for PCa 
remain unclear, and the extent to which 
AR acquires new functions during PCa 
development and progression remains to be 
determined.
AR‑INDUCED GENES MEDIATING PCa 
GROWTH
Consistent with the normal function of 
androgens in prostate being to drive the 
differentiated functions of luminal epithelial 
cells, AR induces many genes coding for 
seminal fluid proteins (such as prostate‑specific 
antigen) and multiple genes in metabolic 
pathways required to support high‑levels of 
protein and lipid synthesis.1,2 Significantly, AR 
does not stimulate the proliferation of normal 
prostate luminal epithelial cells. However, 
AR can clearly stimulate PCa growth and 
androgen deprivation in PCa cell lines causes 
a G0/G1‑cell cycle arrest.3,4 Amongst genes 
that regulate cell cycle, the AR binds to a site 
on the cyclin‑dependent kinase inhibitor p21 
gene and directly increases p21 transcription 
and protein expression.5 In some contexts, 
p21 may stimulate cell cycle progression 
by increasing assembly of cyclin D/CDK4 
complexes, which may be a mechanism that 
contributes to androgen‑stimulated PCa 
growth.
There are data suggesting direct AR 
regulation of other cell cycle genes, but 
most genes driving cell cycle progression 
T
he androgen receptor (AR) is critical 
for the normal development of 
prostate and for its differentiated functions. 
The consistent expression of AR in prostate 
cancer (PCa), and its continued activity in 
PCa that relapse after androgen deprivation 
therapy (castration‑resistant prostate 
cancer (CRPC)), indicate that at least a 
subset of these genes are also critical for PCa 
development and progression. This review 
addressed AR regulated genes that may be 
critical for PCa, and how AR may acquire 
new functions during PCa development 
and progression.
AR is a steroid receptor and member 
of the nuclear receptor family of 
ligand‑activated transcription factors. It 
has a large N‑terminal domain that can 
strongly stimulate transcription, a C‑terminal 
ligand‑binding domain (LBD) that has a 
weaker transactivation function, a central 
DNA‑binding domain and a short hinge 
region between the DNA binding domain 
and LBD that mediates functions including 
its nuclear translocation and degradation. 
In the absence of androgen (testosterone 
or dihydrotestosterone), the AR associates 
with an HSP90 chaperone complex in the 
cytoplasm. In response to androgen binding to 
the LBD, the AR undergoes a conformational 
change that repositions helix 12 to generate a 
binding site for LXXLL‑motifs found in many 
coactivator proteins. Interestingly, in the AR 
this coactivator binding site initially binds to 
an LXXLL‑like motif in the AR N‑terminal 
domain, which may be important for nuclear 
translocation or the initial steps in chromatin 
binding. The liganded AR then forms a 
homodimer in the nucleus and binds to 
in response to androgen do not appear to 
be directly regulated by AR.4 One indirect 
mechanism mediating proliferation in 
response to androgens is an increase in 
TORC1 activity, with a subsequent TORC1 
mediated increase in the translation of 
D‑cyclins.2 The increase in TORC1 activity 
in response to androgen likely reflects the 
ability of AR to stimulate cellular metabolism 
by increasing the expression of multiple 
membrane transporters and other genes 
driving lipid and protein synthesis.
Androgen stimulation also promotes rapid 
degradation of the cyclin‑dependent kinase 
inhibitor p27.3,6 Our recent data indicate 
that this p27 degradation is due to androgen 
stimulation of TORC2, with the subsequent 
phosphorylation and activation of AKT and 
phosphorylation of p27 by AKT at a site that 
enhances p27 degradation (threonine 157).7 
The androgen‑mediated stimulation of 
TORC2 appears to be independent of 
transcription, but its mechanism remains to 
be determined. Interestingly, this AKT site 
on human p27 is not conserved in the mouse, 
and our recent study using a tetracycline 
inducible myristoylated‑AKT indicates 
that AKT driven proliferation in mouse 
prostate epithelium is independent of p27 
degradation.8 These observations suggest that 
studies in mouse models may underestimate 
the oncogenic activity of PI3 kinase/AKT 
pathway activation.
Finally, it should be noted that AR is also 
weakly expressed by subsets of cells in the 
prostate stroma, and that AR in these cells 
can stimulate the expression of growth factors 
such as keratinocyte growth factor/fibroblast 
growth factor 7.9 Through this mechanism, 
AR in stromal cells may indirectly regulate 
growth of the epithelium, and loss of these 
stromal factors likely contributes to prostate 
involution after castration.
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AR‑REPRESSED GENES MEDIATING 
ANDROGEN SIGNALING AND DNA 
SYNTHESIS
The mechanisms through which AR functions 
as a transcriptional activator have been 
extensively characterized. However, androgens 
also decrease the expression of multiple genes 
through direct or indirect mechanisms. One 
indirect mechanism is by binding to and 
interfering with other transcription factors 
such as SP1, which can suppress SP1‑mediated 
transactivation of genes including luteinizing 
hormone and c‑MET.10,11 Other transcription 
factors that may be similarly antagonized 
include RUNX2, JUN and SMAD3.12 AR may 
also suppress the activity of TCF transcription 
factors by binding to and sequestering nuclear 
β‑catenin.13–18
The AR also has been reported to recruit 
certain transcription corepressors such as 
ALIEN, DAX1, HEY and AES, but their roles 
in AR regulation of specific genes remain to 
be determined.19–24 The corepressors NCoR 
and SMRT associate strongly with the LBD 
of unliganded nonsteroid nuclear receptors 
and mediate their transcriptional repression 
functions. In contrast, unliganded steroid 
receptors are not tightly associated with 
chromatin and the roles of NCoR and SMRT 
are less clear. However, the agonist‑liganded 
AR can associate weakly with NCoR and 
SMRT, probably through the AR N‑terminal 
domain, and this interaction can modestly 
suppress AR transcriptional activity.25–28 
Significantly, certain AR antagonists can 
enhance NCoR and SMRT binding to AR, 
which may contribute to their activities. 
Finally, androgen‑mediated transcriptional 
repression has been linked to AR recruitment 
of EZH2 and an increase in the EZH2 
catalyzed repressive H3K27me3 mark.29,30
We recently explored the mechanism 
through which androgens can suppress 
AR mRNA levels, and found that the 
agonist‑liganded AR was functioning directly 
on the AR gene to repress its transcription.31 
This repression was mediated through an 
AR binding site in the second intron of the 
AR gene, and was dependent on the binding 
of a histone demethylase, lysine specific 
demethylase 1 (LSD1, KDM1A) to this site. 
LSD1 has been extensively characterized as 
a transcriptional repressor that functions 
by demethylation of the H3K4me1 and 
H3K4me2 histone marks associated with 
enhancers (due to its catalytic mechanism, 
LSD1 cannot demethylate trimethylated 
lysines).32 LSD1 associates with the protein 
CoREST in a repressive complex that also 
includes histone deactylases (HDAC1 and 
HDAC2), providing a further mechanism for 
transcriptional repression.
In addition to the AR gene, we found that 
AR could similarly repress the expression of 
genes mediating androgen synthesis (AKR1C3 
and HSD17B6), consistent with a negative 
feedback pathway to regulate AR signaling. 
Significantly, androgen repressed genes 
were also highly enriched for genes that are 
required for DNA synthesis.31 This result is 
consistent with a normal physiological role of 
AR being to drive differentiation rather than 
proliferation. The androgen repression of these 
genes is presumably overridden in PCa by 
other oncogenic signal transduction pathways. 
However, an unintended consequence of 
androgen deprivation therapy may be to relieve 
repression of these genes and thereby provide a 
stimulus for proliferation that may contribute 
to eventual relapse. If possible, approaches 
that can selectively block AR activity on 
AR‑stimulated genes, while maintaining or 
enhancing AR repression of genes mediating 
DNA synthesis may be more effective than 
current androgen deprivation therapies.
AR ACQUIRES NEW FUNCTIONS IN 
TMPRSS2:ERG FUSION POSITIVE 
TUMORS
Fusions between the strongly AR regulated 
TMPRSS2 gene and the Ets family transcription 
factor ERG gene, as well as additional fusions 
involving TMPRSS2 or other AR regulated 
genes, have established a genetic mechanism 
through which AR acquires new functions 
during PCa development.33 Several genes 
that may be directly regulated by ERG have 
been identified, but the precise mechanisms 
through which ERG drives PCa development 
have not been clear.34,35
We reported recently that ERG binds to a 
site downstream of the SOX9 gene in human 
PCa cells and thereby opens a binding site for 
AR that is not present in the absence of ERG.36 
This site then functions as an AR regulated 
enhancer resulting in robust androgen 
stimulated induction of SOX9 (Figure 1). ERG 
similarly opens cryptic AR regulated enhancers 
in multiple other genes, but SOX9 appears to 
be the major effector of ERG in human PCa 
cells. In particular, SOX9 has been shown to 
regulate ductal morphogenesis in fetal prostate 
and to maintain stem/progenitor cells in adult 
tissues.37–40 SOX9 overexpression in human PCa 
cells enhances their growth and invasion, while 
SOX9 knockdown suppresses their growth.36,40 
In mouse models, SOX9 overexpression in 
prostate on a Pten−/+ background results in 
high grade dysplastic lesions that can progress 
to invasive PCa, while SOX9 knockdown can 
impair PCa development driven by MYC and 
SV40 T antigen.36,37,41
A recent study showed that ERG 
expression in mouse prostate, similarly to 
ERG in human PCa cells, reprograms AR 
to stimulate the expression of multiple new 
genes.42 However, the ERG and AR‑binding 
site identified at the 3’ end of the human 
SOX9 gene is not conserved in mouse, so 
that ERG overexpression in mouse prostate 
does not increase SOX9.36 This may account 
for the weaker phenotype of transgenic ERG 
versus transgenic SOX9 overexpression in 
mouse prostate. Interestingly, a recent study in 
mouse found that the transcriptional repressor 
Zbtb7a, which behaves as a tumor suppressor 
in mouse PCa models, functions by repressing 
SOX9 transcriptional activity.43 Therefore, 
while ERG does not directly increase SOX9 
expression in mouse, it remains possible that 
it modulates SOX9 activity or downstream 
functions. In any case, identification of the 
critical functions downstream of SOX9 that 
may drive PCa is now a focus of investigation.
FURTHER NOVEL AR FUNCTIONS 
ACQUIRED DURING PCa DEVELOPMENT 
OR PROGRESSION
The spectrum of genes regulated by AR 
during PCa development or progression may 
also be altered by epigenetic mechanisms. 
In a CRPC cell line derived from LNCaP 
cells (LNCaP‑abl), AR was found to have 
a distinct transcriptional program that 
Figure 1: ERG opens cryptic AR regulated enhancer in human SOX9 gene. In the absence of ERG, AR 
binds weakly to a site upstream of the SOX9 gene (S1 site) and weakly suppresses SOX9 expression. In 
TMPRSS2:ERG fusion positive tumors, ERG binds to a site downstream of the SOX9 gene (S2 site). It 
then functions in conjunction with FOXA1 as a pioneer transcription factor to open the site and reveal 
a cryptic AR‑binding site, converting the site into an AR‑regulated enhancer. The S1 site is highly 
conserved across species including mouse, but the S2 site is not conserved. AR: androgen receptor.Invited research highlight  
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included the direct activation of M‑phase 
cell cycle genes such as CDK1 and UBE2C.44 
This reprogramming was associated with 
increased H3K4 methylation and increased 
AR binding to sites in these genes. These 
findings presumably reflect selective pressure 
for tumor cells that have epigenetically 
silenced AR‑regulated genes and opened 
AR‑regulated enhancers controlling genes 
that drive proliferation. Mutations in FOXA1 
and in genes controlling histone methylation 
being found in advanced PCa could possibly 
contribute to AR reprogramming.
EZH2 is one such histone methyltransferase 
that is upregulated in CRPC, and has been well 
characterized as a component of the polycomb 
repressive complex 2 that silences genes through 
H3K27 trimethylation. However, EZH2 also has 
been identified as an AR coactivator that may 
contribute to altering AR function in CRPC. A 
recent study found that EZH2 forms a polycomb 
repressive complex 2 independent complex 
with AR in CRPC cells, which is recruited to 
the cis‑regulatory elements of AR target genes 
including CDK1 and UBE2C.45 Moreover, EZH2 
was found to function as an AR coactivator on 
these genes by a mechanism that is dependent on 
its methyltransferase activity, but independent 
of its ability to methylate H3K27. Finally, this 
AR interaction and coactivator function of 
EZH2 may be mediated by AKT dependent 
phosphorylation. As AKT is generally activated 
in advanced PCa due to PTEN loss, this may 
be a major mechanism contributing to AR 
reprogramming.
Interestingly, AR splice variants lacking 
the LBD, which are increased in CRPC, 
may also regulate a distinct set of genes that 
include genes driving cell cycle progression.46 
The basis for these differences remains 
to be determined, but could reflect novel 
interactions between AR splice variants and 
coactivators including EZH2. Finally, it should 
be emphasized that most of our current 
detailed data on AR regulated genes is derived 
from studies in model systems. Therefore, 
despite the challenges, it will be important to 
translate these findings into clinical samples. 
Indeed, one recent AR ChIP‑seq study in 
human CRPC samples tumors found evidence 
of a transcriptional program that was distinct 
from that found in PCa cell line models.47
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